SCHEMBL286183

SCHEMBL286183

Cc1nc(C=Cc2c(-c3ccccc3)noc2C)sc1C(=O)OCC(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 2/20 0.41
ADORA3 P0DMS8 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285938 0.86 ALDH1A1 (0.48) POLBALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL285937 0.86 ALDH1A1 (0.48) POLBALDH1A1LMNAMAPTSMN1; SMN2
SCHEMBL286040 0.83 SMN1; SMN2 (0.49) POLBALDH1A1MEN1GAAKMT2A
SCHEMBL286041 0.83 SMN1; SMN2 (0.49) POLBALDH1A1MEN1GAAKMT2A
SCHEMBL286104 0.83 POLB (0.44) POLBALOX15TSHRMAPK1ALDH1A1
SCHEMBL286453 0.79 GABRA5 (0.53) ALDH1A1MEN1KMT2ALMNACYP1A2
SCHEMBL286451 0.79 GABRA5 (0.53) ALDH1A1MEN1KMT2ALMNACYP1A2
SCHEMBL285784 0.78 TSHR (0.35) POLBTSHRMAPK1ALDH1A1HSD17B10
SCHEMBL286452 0.78 HPGD (0.46) ALDH1A1MEN1GAAKMT2AMAPT
SCHEMBL286182 0.78 GABRA5 (0.46) ALDH1A1MEN1GAAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed